4DMT reports FY2023 net loss $100.8M; positive 4D-150 wet AMD data, Phase 3 plan Q1 2025

4D Molecular Therapeutics, Inc.

2023-FY EPS reported -$2.58 revenue$20,723,000

Net loss $100.8M in 2023; cash $299M at Dec 2023; Feb 2024 offering $281M net; runway into H1 2027.
4D-150 interim data in wet AMD: favorable safety, no significant inflammation; 24-week data reduced treatment burden vs aflibercept.
Phase 3 trial for 4D-150 in wet AMD expected to start Q1 2025; FDA RMAT and EMA PRIME designations.
Pipeline progress: 4D-710 CF positive interim data; 4D-310 Fabry cardiac improvements; IND for 4D-175 GA expected Q2 2024.
Strategic partnerships: Astellas (up to $942.5M milestones) for ophthalmic vectors; Arbor for CNS gene editing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

4D Molecular Therapeutics, Inc. reported financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 29, 2024, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the year ended December 31, 2023.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

4D Molecular Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-023088

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.